Hillstream BioPharma, Inc. (HILS) has an overall financial health rating of C+ with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2023-10-20.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2023-10-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-10-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-10-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-10-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-10-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-09-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
